HOLLENCREST CAPITAL MANAGEMENT
Position in BEAM — Beam Therapeutics Inc.
CIK 1161722
NEWPORT BEACH, CA
Position in BEAM
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$43,060
+$42,416 QoQ
Shares Held
1,807
+6850.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2022
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BEAM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HOLLENCREST CAPITAL MANAGEMENT holds $1,718,963 across 26 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
11,374 | $927,094 | |
| 2 | LBRX |
Lb Pharmaceuticals Inc
|
13,722 | $445,347 | |
| 3 | CYTK |
Cytokinetics Inc
|
1,200 | $102,228 | |
| 4 | NKTR |
Nektar Therapeutics
|
760 | $53,055 | |
| 5 | IBRX |
ImmunityBio, Inc.
|
5,015 | $43,906 | |
| 6 | ACAD |
Acadia Pharmaceuticals Inc
|
1,000 | $25,300 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
100 | $24,477 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
375 | $20,452 |
All Filings in BEAM
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $43,060 | 1,807 | Shares | Sole | 2026-05-07 | |
| 2024-12-31 | $644 | 26 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $637 | 26 | Shares | Sole | 2024-11-01 | |
| 2024-06-30 | $609 | 26 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $859 | 26 | Shares | Sole | 2024-05-01 | |
| 2023-12-31 | $707 | 26 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $625 | 26 | Shares | Sole | 2023-11-13 | |
| 2023-06-30 | $830 | 26 | Shares | Sole | 2023-08-10 | |
| 2023-03-31 | $796 | 26 | Shares | Sole | 2023-05-16 | |
| 2022-12-31 | $1,016 | 26 | Shares | Sole | 2023-02-07 | |
| No filing history on record for this holder in this stock. | ||||||